ABL1 and acute myeloid leukemia: We previously reported that 5/19 Ph+ CML/AML (acute myeloid leukemia) cell lines (KCL-22, NALM-1, SD-1, SUP-B15 and MHH-TALL-1) were TKI-resistant and that none showed mutations in the kinase domain of BCR-ABL1.